Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health director Tariq Musa reported routine equity activity tied to a prior restricted stock unit (RSU) grant. On April 15, 2026, he exercised 250 Restricted Stock Units at $0.00, converting them into 250 shares of Common Stock. On April 16, 2026, he completed an open-market sale of 116 Common Stock shares at an average price of $84.83 per share.
Following these transactions, Musa directly holds 8,528 shares of Common Stock and 2,749 Restricted Stock Units. The RSU award, granted on March 6, 2023, vests over four years, with 25% vesting on March 15, 2024 and the remaining 75% vesting monthly over the next three years.
Guardant Health Chief Legal Officer John G. Saia reported routine equity compensation activity. On April 15, 2026, 7,569 restricted stock units converted into an equal number of Guardant Health common shares at no exercise price as part of a scheduled vesting.
Of these vested shares, 3,970 were retained by the company to satisfy Mr. Saia’s tax withholding obligations at a reference price of $84.86 per share, which is a tax-withholding disposition rather than an open-market sale. After these transactions, he directly owns 65,950 shares of Guardant Health common stock.
Guardant Health reported a Form 144 notice relating to the proposed sale of Common stock. The filing lists 9,840 Common shares with a filing date of 04/16/2026 via Charles Schwab. The excerpt also notes a restricted stock lapse on 02/15/2026 and a reported sale of 348 shares by Musa Tariq on 03/18/2026.
Guardant Health Chief People Officer sells shares in open market
Guardant Health, Inc.'s Chief People Officer, Terilyn J. Monroe, reported an open-market sale of 3,832 shares of Common Stock at $92.68 per share. After this transaction, she continues to hold 20,990 Guardant Health shares directly.
Guardant Health submitted a Form 144 disclosing proposed sales of common stock related to equity compensation and restricted stock lapses. The filing lists a Charles Schwab & Co. intermediary entry for 3,832 shares dated 04/01/2026 and two past sales by Terilyn J. Monroe of 10,031 and 8,571 shares on 01/07/2026 and 01/21/2026, respectively.
Guardant Health Chief Legal Officer John G. Saia reported routine equity compensation activity. On April 1, 2026, multiple tranches of restricted stock units vested and were exercised into a total of 11,461 shares of Common Stock at an exercise price of $0.00 per share.
To cover tax obligations related to the vesting, 6,013 Common Stock shares were retained by Guardant Health at a price of $91.15 per share, as disclosed in the footnotes. After these transactions, Saia directly held 62,351 Common Stock shares. The RSU awards were originally granted between November 2022 and March 2025 and vest over three- to four-year periods in quarterly installments.
Guardant Health, Inc. Chief People Officer Terilyn J. Monroe reported routine equity compensation activity tied to restricted stock units. On April 1, 2026, she acquired 8,019 shares of common stock upon vesting and related derivative exercises, then had 4,187 shares withheld by the company to cover tax obligations at $91.15 per share. After these transactions, she directly held 24,822 shares of common stock. The filing reflects compensation and tax withholding mechanics rather than open-market buying or selling.
Guardant Health Chief Information Officer Kumud Kalia reported routine equity compensation activity involving restricted stock units. On April 1, 2026, several restricted stock unit awards converted into a total of 10,044 shares of Common Stock, reflecting scheduled vesting from previously granted awards.
To cover related tax obligations, 5,092 Common Stock shares were withheld by Guardant Health at $91.15 per share, as described in the footnotes, and were not sold in the open market. After these transactions, Kalia directly holds 49,249 Common Stock shares, indicating an overall increase in his equity stake despite the tax withholding.
Guardant Health Chief Commercial Officer Chris Freeman reported routine equity compensation activity. On April 1, 2026, multiple installments of his restricted stock unit awards vested, resulting in the acquisition of 11,213 shares of Common Stock at an exercise price of $0.00 per share.
To cover tax obligations tied to this vesting, 4,750 shares were withheld by Guardant Health at a price of $91.15 per share, as noted in the footnotes. After these transactions, Freeman directly owned 60,034 shares of Guardant Health common stock. The RSU awards were originally granted between November 7, 2022 and March 12, 2025 and vest over three- to four-year periods in quarterly installments.
Guardant Health, Inc. Chief Medical Officer Craig Eagle reported routine equity compensation activity as several restricted stock unit awards vested on April 1, 2026. He exercised RSUs to acquire a total of 11,400 shares of common stock at an exercise price of $0.00 per share.
To satisfy related tax obligations, 5,779 shares of common stock were retained by the company at $91.15 per share, as described in the footnotes, rather than sold on the open market. Following these transactions, Eagle directly holds 72,001 shares of Guardant Health common stock.